Construction of Influenza A/H1N1 Virosomal Nanobioparticles
Authors
Abstract:
Background and Aims: Influenza is one of the main respiratory infections of humans, responsible for 300,000–500,000 annual deaths world-wide. Vaccination is one of the best ways to prevent infections including influenza. Influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the ribonucleoprotein (RNP). A virosomal influenza vaccine has recently been commercially available in Europe (Inflexal V®). The virosome is prepared by membrane solubilization and reconstitution. A new method based on dialyzable detergent has been developed to produce virosomes from an A/H3N2 influenza virus. Methods: In this study attempt was made to construct a virosomal nanobioparticle of influenza A/ PR8 (H1N1). The Madine-Darby Canine kidney (MDCK) cell line was cultured and infected with influenza virus strain A/PR8 and the culture media were harvested and the virus was purified by ultracentrifugation and concentrated by ultrafiltration. Purified influenza virus was treated with 1, 2-dicaproyl-sn-glycero-3-phosphocholine (DCPC) as a solubilizing detergent to resolve the viral envelope. Ribonucleoprotein was sedimented by ultracentrifugation and the supernatant consisting phospholipids and glycoproteins of influenza virus was reconstituted by removal of DCPC using overnight dialysis against Hank's Buffered Saline (HBS) solution. Results: Finally, the empty influenza virus envelope, called virosome, was observed by transmission electron microscopy (TEM). The size of these particles was estimated to be 50-100 nm. Conclusion: Virosome has been used as a new vaccine formulation and since it is a nontoxic adjuvant carrier it can be used to improve the present commercialized and new vaccines.
similar resources
construction of influenza a/h1n1 virosomal nanobioparticles
background and aims: influenza is one of the main respiratory infections of humans, responsible for 300,000–500,000 annual deaths world-wide. vaccination is one of the best ways to prevent infections including influenza. influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the ribonucleoprotein (rnp). a virosoma...
full textPredicting AH1N1 2009 influenza epidemic in Southeast Europe
AIM To use the data on the AH1N1 2009 influenza epidemic in the Southern hemisphere countries to predict the course and size of the upcoming influenza epidemic in South-Eastern Europe (SEE) countries and other regions of the World with temperate climate. METHOD We used a comparative epidemiological method to evaluate accessible electronic data on laboratory-confirmed deaths from AH1N1 2009 in...
full textVariability of influenza AH1N1 infections in a neonatal unit in Spain.
We describe three positive influenza AH1N1 cases in a neonatal unit during the influenza pandemic in Spain. One term baby presented with an upper respiratory tract infection, another preterm infant with an apnea episode following nosocomial infection, and thirdly, a term infant of a mother with influenza AH1N1 had severe respiratory distress and pneumothoraces needing high-frequency ventilation.
full textIncidental late diagnosis of cystic fibrosis following AH1N1 influenza virus pneumonia: a case report
BACKGROUND Cystic fibrosis is an autosomal recessive disorder characterized by chronic progressive multisystem involvement. AH1N1 virus infections caused classic influenza symptoms in the majority of cystic fibrosis patients while others experienced severe outcomes. CASE PRESENTATION We report a case of late incidental cystic fibrosis diagnosis in a young Caucasian man suffering from respirat...
full textUtility of virosomal adjuvated influenza vaccines: a review of the literature.
In spite of the efforts of the World Health Organization (WHO), influenza continues to be a major public health problem, both because of its impact on the health of subjects at risk, such as the elderly, and because of the economic burden that it places on society. Adjuvants are agents which, when incorporated into vaccines, enhance the immunogenicity of their antigens. The need for ever more i...
full textMy Resources
Journal title
volume 5 issue None
pages 13- 18
publication date 2011-05
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023